Aura Biosciences, Inc. Total Liabilities
Aura Biosciences, Inc. (AURA) had Total Liabilities of $32.86 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-11
- 2026-06-30: Liabilities $32.86M.
- 2026-03-31: Liabilities $30.43M.
- 2025-12-31: Liabilities $32.52M.
- 2025-09-30: Liabilities $33.36M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $32.86M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $30.43M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $32.52M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $33.36M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $29.77M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $27.43M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $30.53M 10-K · filed 2026-03-30 |
| 2024-09-30 | $30.67M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $26.83M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $26.24M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $29.23M 10-K · filed 2025-03-24 |
| 2023-09-30 | $28.05M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $26.30M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $25.76M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $28.35M 10-K · filed 2024-03-27 |
| 2022-09-30 | $28.09M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.93M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $5.34M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $7.71M 10-K · filed 2023-03-15 |
| 2021-09-30 | $6.42M 10-Q · filed 2021-11-24 |
| 2020-12-31 | $2.74M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |